Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Plans to Raise up to $17.3M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion has filed to offer more than 2 million shares of its common stock to raise up to $17.3 million.

In a Form S-1 filed today with the US Securities and Exchange Commission, the Austin, Texas-based molecular diagnostics firm said it plans to offer up to 2,098,539 shares of its stock at a maximum price of $8.22 per share.

Proceeds from the raise will be used by Vermillion to expand into international markets, fund clinical trials for its peripheral artery disease test, "pursue opportunities to diversity our product and service lines and offerings," and general corporate purposes.

Roth Capital Partners is the underwriter on the offering.

In September 2009, Vermillion received clearance from the US Food and Drug Administration for its OVA1 triage ovarian cancer diagnostic, co-developed and co-marketed by Quest Diagnostics.

Earlier this month the company said that for 2010, it had performed an estimated 6,155 VA1 tests in 2010, exceeding a revised guidance of between 5,000 and 5,500 tests. The company had initially provided guidance of between 8,000 and 10,000 OVA1 tests for 2010.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.